By Edward Winnick

SAN FRANCISCO (GenomeWeb News) – Caliper Life Sciences hopes to receive the CE IVD Mark this year for its new LabChip Dx instrument as it looks to potential partnerships to help build content for the new platform, President and CEO Kevin Hrusovsky told GenomeWeb Daily News.

Speaking in advance of Caliper's presentation Thursday at the JP Morgan Healthcare Conference here, he also said his firm believes it has the tools pharma firms will want in developing companion diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.